Global Pleuritis Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Pleuritis Market Size

• The global pleuritis market size was valued at USD 2.10 billion in 2024 and is expected to reach USD 3.03 billion by 2032, at a CAGR of 4.70% during the forecast period
• The moreover, advancements in diagnostic imaging, improved therapeutic management, and the development of targeted anti-inflammatory and antibiotic treatments are enhancing patient outcomes and fostering market expansion
• In addition, growing healthcare expenditure, heightened awareness of pleural diseases, and an expanding elderly population susceptible to respiratory complications are collectively accelerating the adoption of pleuritis-related treatments, thereby strengthening the industry’s overall growth trajectory

Pleuritis Market Analysis

• Pleuritis, an inflammation of the pleural membranes surrounding the lungs, is gaining medical importance globally due to the rising prevalence of respiratory infections, autoimmune diseases, and chronic pulmonary disorders. The market encompasses diagnostic procedures, therapeutic treatments, and healthcare services addressing both infectious and non-infectious pleural conditions
• The increasing cases of tuberculosis, pneumonia, and lupus-related pleuritis, coupled with advancements in imaging diagnostics and anti-inflammatory therapies, are propelling market growth. Moreover, rising awareness of early disease detection and improved access to healthcare facilities are further supporting industry expansion
• North America dominated the global pleuritis market with the largest revenue share of 41.8% in 2024, attributed to advanced healthcare infrastructure, early adoption of diagnostic imaging, and strong R&D investments in respiratory disease management, with the U.S. leading the regional market
• The Asia-Pacific region is expected to witness the fastest growth during the forecast period, driven by a high tuberculosis burden, growing healthcare expenditure, and improving access to diagnostic and treatment services in countries such as India and China
• The Antibiotics segment dominated the market with the largest market share of 37.9% in 2024 under the Treatment Type category, owing to the high incidence of bacterial pleuritis cases and the continued reliance on antibiotic therapy as the first-line treatment for infection-induced pleural inflammation

Report Scope and Pleuritis Market Segmentation    

Pleuritis Market Trends

Advancements in AI-Assisted Diagnostics and Imaging

• A notable trend in the global pleuritis market is the integration of artificial intelligence (AI) with diagnostic imaging devices, enabling more precise detection and assessment of pleural inflammation
  • For instance, AI-powered ultrasound and CT imaging systems can automatically identify pleural effusions and quantify inflammation, assisting clinicians in faster diagnosis and treatment planning
• Machine learning algorithms also help predict disease progression and recurrence, allowing for personalized treatment strategies based on patient history and imaging data
• The use of AI in diagnostic workflows enhances the accuracy of pleuritis detection, reduces human error, and optimizes workflow efficiency in hospitals and diagnostic laboratories
• This trend is driving the development of intelligent diagnostic platforms that combine imaging, lab results, and patient data for comprehensive pleuritis management
• The growing adoption of AI-assisted imaging is expected to elevate standards of care, improve patient outcomes, and streamline clinical decision-making in both developed and emerging healthcare markets
• Increasing integration of wearable respiratory monitoring devices with digital platforms allows for continuous monitoring of patients at risk of pleuritis, enabling early intervention
• Telemedicine adoption is rising, allowing clinicians to remotely assess symptoms and imaging results, further supporting early diagnosis and personalized treatment plans

Pleuritis Market Dynamics

Driver

Increasing Prevalence of Respiratory Infections and Autoimmune Disorders

• The rising incidence of tuberculosis, pneumonia, and autoimmune diseases is a primary driver for the growing demand for pleuritis diagnostics and treatments worldwide
  • For instance, the high burden of tuberculosis in Asia-Pacific has led to expanded hospital services and diagnostic screening programs targeting pleural complications
• Enhanced awareness of early disease detection and proactive treatment strategies is motivating healthcare providers to adopt advanced diagnostic tools and therapies
• Moreover, the growing elderly population, which is more susceptible to respiratory complications, is contributing to increased hospital visits and treatment adoption for pleuritis
• The convergence of rising disease prevalence, improved healthcare access, and focus on early intervention is accelerating market growth for pleuritis management solutions
• Governments and private healthcare providers are increasingly investing in pleuritis-related diagnostics and therapeutics to reduce morbidity and improve clinical outcomes
• Expansion of public health initiatives targeting respiratory infections is further driving early diagnosis and timely treatment for pleuritis
• Collaborations between diagnostic companies and hospitals to develop rapid point-of-care testing for pleuritis are increasing adoption and improving patient management

Restraint/Challenge

Limited Access to Advanced Diagnostics and High Treatment Costs

• A key challenge in the pleuritis market is the limited availability of advanced imaging and laboratory diagnostic facilities in certain regions, particularly in low- and middle-income countries
  • For instance, many rural and underdeveloped areas lack access to CT scans or AI-enabled ultrasound devices, delaying accurate diagnosis and effective treatment
• High costs associated with advanced diagnostic procedures and therapeutic interventions can restrict adoption among price-sensitive patients and healthcare facilities
• While some generic antibiotics and anti-inflammatory drugs are affordable, newer biologics and targeted therapies remain expensive, limiting their use in widespread clinical practice
• Addressing these challenges requires improving infrastructure, reducing costs through local manufacturing, and expanding insurance coverage to enhance patient access
• Overcoming these barriers is critical for equitable market growth and ensuring timely pleuritis management across diverse geographies
• Regulatory hurdles and inconsistent reimbursement policies in different countries can delay the adoption of new diagnostic tools and therapies for pleuritis
• Limited awareness among patients regarding pleuritis symptoms and treatment options also hampers early diagnosis and effective disease management

Pleuritis Market Scope

The market is segmented on the basis of diagnostic type, treatment type, end user, mode of purchase, and distribution channel.

• By Diagnostic Type

On the basis of diagnostic type, the pleuritis market is segmented into thoracentesis, imaging devices, blood test, and others. The imaging devices segment dominated the market with the largest revenue share in 2024, driven by the growing reliance on advanced diagnostic tools such as chest X-rays, CT scans, and AI-assisted ultrasound for accurate detection of pleural inflammation. Imaging diagnostics are preferred due to their non-invasive nature, faster results, and ability to identify both effusions and underlying conditions contributing to pleuritis. Hospitals and diagnostic laboratories invest heavily in imaging infrastructure to improve early detection rates and patient management. Technological advancements, including 3D imaging and AI-assisted analysis, have further strengthened the adoption of imaging devices. Moreover, imaging diagnostics are critical in guiding treatment decisions, including drainage procedures and monitoring the effectiveness of pharmacological interventions.

The thoracentesis segment is expected to witness the fastest growth during 2025–2032, fueled by its role as both a diagnostic and therapeutic procedure. Thoracentesis allows direct sampling of pleural fluid for microbiological, cytological, and biochemical analysis, aiding in precise diagnosis and treatment planning. The rising prevalence of pleural effusions associated with infections and autoimmune disorders is boosting the adoption of thoracentesis. Increasing clinician expertise, minimally invasive techniques, and improved patient safety measures further support market expansion. Growing awareness among patients regarding procedure benefits is also contributing to higher adoption rates in hospitals and specialized clinics.

• By Treatment Type

On the basis of treatment type, the pleuritis market is segmented into antibiotics, antifungals, blood thinners, nonsteroidal anti-inflammatory drugs (NSAIDs), and others. The antibiotics segment held the largest market share of 37.9% in 2024, driven by the high prevalence of bacterial pleuritis cases and the established role of antibiotics as the first-line treatment for infection-induced pleural inflammation. Hospitals and clinics prioritize antibiotics for their effectiveness in managing bacterial causes and preventing complications such as empyema. The segment benefits from widespread clinical guidelines and physician familiarity, facilitating quick adoption. Availability of broad-spectrum antibiotics and oral formulations enhances accessibility in both inpatient and outpatient settings. Increasing physician awareness of drug-resistant strains and optimized dosing regimens is also boosting demand.

The NSAIDs segment is expected to register the fastest growth during 2025–2032 due to their use in managing inflammation and pleuritic pain in non-infectious cases. NSAIDs provide symptomatic relief, improve patient comfort, and are often used alongside other therapies. Growing emphasis on patient-centered care and pain management is increasing NSAID prescriptions in hospitals and clinics. Moreover, over-the-counter availability in some regions is expanding access for patients with mild pleuritic symptoms. Rising awareness of chronic inflammatory conditions contributing to pleuritis is also supporting market growth in this segment.

• By End User

On the basis of end user, the pleuritis market is segmented into hospitals, clinics, diagnostic laboratories, and others. The hospitals segment dominated the market with the largest share of 45.2% in 2024, driven by the availability of advanced diagnostic imaging and specialized therapeutic services. Hospitals are preferred for pleuritis management due to the complexity of care required, including thoracentesis, advanced imaging, and monitoring of severe cases. The segment benefits from higher patient inflow, skilled specialists, and access to a full range of treatment options. Hospitals are also adopting AI-assisted diagnostic systems to improve detection and optimize treatment protocols. Increasing hospital investments in respiratory care units further strengthen market dominance.

The diagnostic laboratories segment is expected to witness the fastest growth during 2025–2032, fueled by the rising demand for rapid and accurate pleuritis diagnosis. Laboratories offer specialized testing services, including pleural fluid analysis, biochemical assays, and molecular diagnostics. The growing trend of outsourcing diagnostic services by hospitals and clinics is expanding laboratory market opportunities. Investment in AI-assisted laboratory equipment is improving turnaround times and accuracy. Rising prevalence of pleuritis and associated comorbidities is increasing patient referrals to diagnostic labs, supporting rapid adoption.

• By Mode of Purchase

On the basis of mode of purchase, the market is segmented into prescription and over the counter (OTC). The prescription segment dominated the market with the largest share of 78% in 2024, owing to the need for physician supervision in prescribing antibiotics, antifungals, blood thinners, and other pleuritis therapies. Prescription-based purchases ensure correct dosing, monitoring for side effects, and adherence to treatment protocols. Hospitals and clinics serve as the primary points for prescription distribution, ensuring controlled and effective treatment. Regulatory frameworks in most countries also mandate prescription-only access for certain medications, supporting market dominance. Increasing awareness of treatment compliance and antimicrobial resistance is reinforcing prescription-based adoption.

The OTC segment is expected to witness the fastest growth during 2025–2032, driven by increasing availability of NSAIDs and pain-relief medications for mild pleuritis symptoms. Rising self-medication practices in emerging markets, combined with patient education on symptom management, are supporting OTC adoption. Convenience and affordability are key factors fueling growth in this segment. Retail pharmacies and online platforms further facilitate easy access to OTC medications, expanding the market.

• By Distribution Channel

On the basis of distribution channel, the pleuritis market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment dominated the market with the largest share of 50.6% in 2024, driven by in-hospital dispensing of prescription medications and direct access to therapeutic treatments for pleuritis patients. Hospitals often provide integrated services including diagnostics, treatment, and patient monitoring, making hospital pharmacies a key distribution point. Availability of specialized medications and emergency support further strengthens their market position. Partnerships between hospitals and pharmaceutical companies ensure uninterrupted supply of essential drugs. Increasing hospital admissions for respiratory conditions also supports segment dominance.

The online pharmacies segment is expected to witness the fastest growth during 2025–2032, fueled by increasing e-commerce penetration, patient preference for home delivery, and rising adoption of digital healthcare solutions. Online platforms offer convenience, privacy, and broader product availability, particularly in urban and semi-urban regions. Integration with telemedicine services is further enhancing online pharmacy usage. Rising digital literacy and mobile health applications are accelerating growth. Online pharmacies also provide opportunities for subscription-based medication delivery and automated reminders, supporting patient adherence and market expansion.

Pleuritis Market Regional Analysis

• North America dominated the global pleuritis market with the largest revenue share of 41.8% in 2024, attributed to advanced healthcare infrastructure, early adoption of diagnostic imaging, and strong R&D investments in respiratory disease management, with the U.S. leading the regional market
• Patients and healthcare providers in the region prioritize early detection and effective management of pleuritis, leveraging advanced imaging technologies, AI-assisted diagnostics, and a broad range of treatment options
• The region’s dominance is further supported by high healthcare expenditure, strong R&D investments in respiratory diseases, and well-established hospital and diagnostic networks, making North America a key market for pleuritis management solutions

U.S. Pleuritis Market Insight

The U.S. pleuritis market captured the largest revenue share of 42% in 2024 within North America, driven by advanced healthcare infrastructure and high awareness of respiratory diseases. Patients and healthcare providers are increasingly prioritizing early diagnosis and effective management of pleuritis through advanced imaging devices, AI-assisted diagnostics, and targeted therapies. The growing prevalence of tuberculosis, pneumonia, and autoimmune disorders further propels market growth. In addition, rising healthcare expenditure and well-established hospital networks support widespread adoption of diagnostic and treatment services. Government initiatives and insurance coverage promoting respiratory care are also contributing to market expansion.

Europe Pleuritis Market Insight

The Europe pleuritis market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing respiratory disease prevalence and stringent healthcare standards. Enhanced focus on early detection, coupled with rising adoption of advanced imaging and laboratory diagnostics, is fostering market growth. European healthcare systems are investing in AI-assisted diagnostics and innovative treatment options to improve patient outcomes. Urbanization, rising geriatric population, and higher disposable incomes are increasing demand for comprehensive pleuritis management. Moreover, the adoption of telemedicine and specialized respiratory clinics supports better accessibility and faster diagnosis. The market is witnessing significant growth across hospitals, clinics, and diagnostic laboratories in both new and renovated healthcare facilities.

U.K. Pleuritis Market Insight

The U.K. pleuritis market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing awareness of pleural diseases and early intervention strategies. Rising incidences of pneumonia, tuberculosis, and autoimmune conditions are encouraging hospitals and clinics to adopt advanced diagnostic and treatment solutions. In addition, the country’s strong healthcare infrastructure and widespread use of imaging technologies, such as CT scans and ultrasound, are supporting market growth. Government healthcare programs promoting respiratory health and funding for advanced therapies further contribute to market expansion. The increasing role of private diagnostic laboratories is enhancing accessibility to specialized pleuritis testing. The U.K.’s emphasis on research and clinical trials is also stimulating adoption of innovative therapeutic options.

Germany Pleuritis Market Insight

The Germany pleuritis market is expected to expand at a considerable CAGR during the forecast period, fueled by rising awareness of respiratory disorders and increasing demand for advanced diagnostics and treatment solutions. Germany’s robust healthcare infrastructure and focus on technological innovation support widespread adoption of imaging devices, thoracentesis procedures, and AI-assisted diagnostic tools. Hospitals and specialized respiratory clinics are at the forefront of offering comprehensive pleuritis management. Patient preference for accurate, minimally invasive diagnostics is further driving market growth. Government initiatives to improve chronic disease management and investment in advanced laboratory facilities are strengthening the market. The adoption of telehealth solutions and integration with electronic health records enhances diagnosis and follow-up care.

Asia-Pacific Pleuritis Market Insight

The Asia-Pacific pleuritis market is poised to grow at the fastest CAGR of XX% during 2025–2032, driven by high prevalence of tuberculosis, pneumonia, and other respiratory infections. Increasing urbanization, rising disposable incomes, and expanding healthcare infrastructure in countries such as China, India, and Japan are supporting market expansion. Growing awareness of early diagnosis and access to advanced imaging and laboratory diagnostics are accelerating adoption. Government initiatives promoting respiratory health, coupled with investments in telemedicine and AI-assisted diagnostic systems, further boost the market. Emerging healthcare facilities and specialized diagnostic laboratories are increasing accessibility across urban and semi-urban regions. In addition, local manufacturing of diagnostic devices and pharmaceuticals is enhancing affordability and availability.

Japan Pleuritis Market Insight

The Japan pleuritis market is gaining momentum due to a high prevalence of respiratory diseases, rapid urbanization, and a strong focus on patient-centered care. Advanced imaging technologies, AI-assisted diagnostics, and integration of hospital information systems support timely diagnosis and effective management. The aging population in Japan is driving demand for non-invasive and convenient diagnostic procedures. Hospitals and clinics are increasingly adopting advanced thoracentesis techniques and laboratory testing for accurate pleuritis detection. Government initiatives for respiratory disease monitoring and improved healthcare funding are further supporting market growth. Rising awareness among patients and caregivers about early intervention is enhancing treatment adoption across residential and commercial healthcare facilities.

India Pleuritis Market Insight

The India pleuritis market accounted for the largest market revenue share in Asia-Pacific in 2024, attributed to a high burden of tuberculosis and pneumonia, rapid urbanization, and increasing healthcare awareness. Hospitals and diagnostic laboratories are expanding their pleuritis management services to meet growing patient demand. Affordable diagnostic and treatment solutions, coupled with government initiatives promoting respiratory health and vaccination programs, are supporting market growth. Rising disposable incomes and increasing healthcare accessibility in urban and semi-urban areas further drive adoption. Telemedicine and AI-assisted imaging are becoming more prevalent, improving early diagnosis and treatment monitoring. The presence of domestic pharmaceutical manufacturers providing cost-effective antibiotics and anti-inflammatory drugs is also propelling market expansion.

Pleuritis Market Share

The Pleuritis industry is primarily led by well-established companies, including:

• Scanlan International, (U.S.)
• Olympus Corporation (Japan)
• Wexler Surgical (U.S.)
• Sontec Instruments, Inc. (U.S.)
• Integra LifeSciences Corporation (U.S.)
• Delacroix-Chevalier (France)
• Boston Medical Products, Inc. (U.S.)
• Avik Pharmaceutical Ltd. (India)
• Hovione (Portugal)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Merck & Co., Inc. (U.S.)
• GSK plc (U.K.)
• Boehringer Ingelheim International GmbH (Germany)
• Sanofi (France)
• AbbVie Inc. (U.S.)
• B. Braun SE (Germany)
• BD (U.S.)
• Bicakcilar (Turkey)
• Biometrix Corporation (U.S.)

What are the Recent Developments in Global Pleuritis Market?

• In October 2025, A clinical trial initiated aimed to evaluate the efficacy of prednisone in preventing recurrent pleural effusions in patients with non-specific pleuritis. This study addresses a significant gap in treatment options for this condition
• In October 2025, a study introduced a novel semi-supervised deep learning framework named Teacher-Teaching Assistant-Student (TTAS) for estimating pleural effusion volume from contrast-enhanced CT images. The TTAS model demonstrated superior segmentation performance, achieving a mean Dice score of 0.82 and a four-fold lower mean Absolute Volume Difference compared to existing models
• In August 2025, The Pulmonary Fibrosis Foundation highlighted several clinical trials, focusing on treatments for pulmonary fibrosis, a condition related to pleuritis. These trials are essential in the quest for new treatments and a cure for related diseases
• In June 2025, the Pulmonary Fibrosis Foundation showcased various clinical trials, emphasizing the importance of clinical trial participants in the search for new treatments and cures for pulmonary diseases, including those related to pleuritis
• In March 2025, Memorial Healthcare System participated in a groundbreaking clinical trial for an innovative pleural effusion treatment. The trial concluded in March, and with FDA approval already secured, the device is expected to reach the general market soon after

SKU-61397